TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11871738
Drug: Individualized amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized amino acid solution during the last 5 days (Experimental group)
Study: 11871738
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received total parenteral nutrition for 10 days
Study: 10502210
Drug: Enalapril 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 40 mg daily (E40)
Study: 10502210
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg daily (E10)
Study: 10502210
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg daily (E20)
Study: 10502210
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg daily (E10)
Study: 1702476
Drug: Single fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fraction radiation treatment (8, 10, 12, 15Gy)
Study: 1702476
Drug: Multifraction dose
Normalized name: Titanium Dioxide 1.88 mg in 40 mL / OCTINOXATE 1.4 mg in 40 mL TOPICAL CREAM [Camellia Multiaction UV Sun Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifraction dose schedule (5Gy x 4, 5Gy x 5, 5Gy x 6)
Study: 28810721
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus (SRL) with extended-release tacrolimus (ER-TAC)
Study: 28810721
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) with extended-release tacrolimus (ER-TAC)
Study: 25391263
Drug: CRS followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRS followed by HIPEC and then systemic chemotherapy (Group A)
Study: 25391263
Drug: CRS only
Normalized name: CRS-207
DrugBank: CRS-207 (DB17323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRS only and systemic chemotherapy (Group B)
Study: 16118355
Drug: Sham manipulative
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham manipulative treatment
Study: 14643625
Drug: 12-week functional
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week functional exercise programme (40-min sessions, twice a week)
Study: 18318773
Drug: Udenafil 100
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Udenafil 100 mg
Study: 12297166
Drug: CRP>5mg/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP>5mg/l
Study: 12297166
Drug: CRP<5mg/l
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP<5mg/l
Study: 10078671
Drug: Neostigmine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (all doses)
Study: 2158140
Drug: CY 222
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CY 222 (15,000 U AXa IC) administered via subcutaneous injection once daily for 14 days
Study: 27632215
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (DEX implant) 0.7 mg every 5 months
Study: 27632215
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg administered as per European Summary of Product Characteristics
Study: 26337664
Drug: Dexamethasone intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone intravitreal implant (DEX implant)
Study: 22293876
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg intravenously, twice daily for 5 days
Study: 22293876
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg intravenously, twice daily for 5 days
Study: 19059324
Drug: Novel fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel fixed dose combination tablet containing 300mg zidovudine (AZT) and 160mg lamivudine (3TC)
Study: 19059324
Drug: Duovir tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duovir tablet
Study: 29959799
Drug: Jintrolong® 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintrolong® 0.01 mg/kg
Study: 29959799
Drug: Jintrolong® 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintrolong® 0.06 mg/kg
Study: 29959799
Drug: Jintrolong® 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintrolong® 0.2 mg/kg
Study: 29959799
Drug: Jintrolong® 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintrolong® 0.5 mg/kg
Study: 29959799
Drug: Jintrolong® 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintrolong® 0.8 mg/kg
Study: 29959799
Drug: Conventional rhGH
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rhGH 0.067 mg/kg
Study: 29959799
Drug: Jintrolong® 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintrolong® 0.1 mg/kg
Study: 29959799
Drug: Jintrolong® 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintrolong® 0.4 mg/kg
Study: 31695332
Drug: CoQ10 liquid
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 liquid supplementation (100 mg/day for 3 months)
Study: 29246188
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg orally three times a day for 100 days
Study: 25029835
Drug: Pizhen treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizhen treatment, once a week for 2 weeks (1 treatment course)
Study: 22870676
Drug: Pizhen treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizhen treatment
Study: 19527383
Drug: Education with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education with pill count
Study: 19527383
Drug: Pill count
Normalized name: Pill Counting Tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill count alone
Study: 9817625
Drug: Sertraline (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50-150 mg/day)
Study: 6264825
Drug: Cl2MDP (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cl2MDP (1600 mg daily for 12 weeks)
Study: 31477359
Drug: Conventional Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Active Drug Mixture (CADM)
Study: 29030802
Drug: Stretta treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretta treatment
Study: 24913739
Drug: Facemask (FM)
Normalized name: FM-VP4
DrugBank: FM-VP4 (DB05449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask (FM) therapy
Study: 24913739
Drug: Double-plate appliance/facemask
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-plate appliance/facemask (DPA-FM) therapy
Study: 20102913
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol)
Study: 14687046
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 300 mg twice daily
Study: 14687046
Drug: S-adenosyl-l-methionine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-l-methionine 500 mg twice daily
Study: 12452381
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine before electroacupuncture
Study: 9408704
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal ring (CVR) releasing 20 micrograms ethinyl estradiol and 1 mg of norethindrone acetate daily over two successive cycles with three different insertion regimens
Study: 23383975
Drug: Saw palmetto
Normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saw palmetto (320 mg gelcap daily for 24 weeks, then 2 gelcaps daily for 24 weeks, then 3 gelcaps daily for 24 weeks)
Study: 22608494
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (vitamin E 800 mg, C 500 mg, zinc 40 mg) for 6 months
Study: 22608494
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (pegylated interferon combined with ribavirin)
Study: 17150287
Drug: 23-valent Pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent Pneumococcal Polysaccharide Vaccine (23vPPV) during the third trimester or at delivery
Study: 15149751
Drug: Permixon 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permixon 320 mg/day
Study: 11255445
Drug: Rivastigmine treatment
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine treatment (2 to 12 mg/d) for 26 weeks after 26 weeks of placebo treatment
Study: 3555386
Drug: Adjunctive imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive imipramine hydrochloride treatment
Study: 1790567
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1 mg/kg)
Study: 405029
Drug: Meptazinol administered
Normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol administered rectally
Study: 19279518
Drug: Rosuvastatin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (2.5 mg/day)
Study: 20529243
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/day)
Study: 30696326
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (12 weeks of supervised training twice weekly including interval-based aerobic exercise and resistance training)
Study: 25530107
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate sodium concentration (5 mEq/L below serum sodium)
Study: 25530107
Drug: High dialysate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dialysate sodium concentration (5 mEq/L above serum sodium)
Study: 18492531
Drug: MAS063DP cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAS063DP cream (n = 72)
Study: 18492531
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream (n = 70)
Study: 16812973
Drug: Etanercept (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (1 mg/kg)
Study: 16812973
Drug: Etanercept (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (2 x 25 mg)
Study: 16812973
Drug: Biological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatment
Study: 7779574
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zinc gluconate twice (the evening before and 30 min before the test)
Study: 1970070
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition supplement (250 ml, 20 g protein, 254 kcal) for a mean of 32 days
Study: 31869755
Drug: LTG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG group during inactive pill with levonorgestrel
Study: 31869755
Drug: LTG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG group during inactive pill with drospirenon
Study: 31869755
Drug: LTG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTG group during inactive pill with gestoden
Study: 31708182
Drug: RTS,S/AS01 malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 malaria vaccine (4 doses)
Study: 31708182
Drug: RTS,S/AS01 malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 malaria vaccine (3 doses) plus 1 comparator vaccine dose
Study: 31708182
Drug: Comparator vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator vaccine doses (4 doses)
Study: 29643323
Drug: voglibose (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose (0.2 mg/meal thrice daily)
Study: 22616316
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg of morphine (group M1)
Study: 22616316
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of morphine (group M2)
Study: 20045479
Drug: Pegfilgrastim (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegfilgrastim (single 6 mg dose)
Study: 18022544
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies (unconjugated and conjugated)
Study: 18022544
Drug: Antibody conjugates
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibody conjugates
Study: 11856086
Drug: ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (8 mg intravenously)
Study: 10438182
Drug: Rimactane (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimactane (600 mg)
Study: 10438182
Drug: Generic rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic rifampicin preparations (600 mg)
Study: 7563559
Drug: 11‐mg/d dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11‐mg/d dose of transdermal nicotine
Study: 7563559
Drug: 22‐mg/d dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22‐mg/d dose of transdermal nicotine
Study: 7563559
Drug: 44‐mg/d dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44‐mg/d dose of transdermal nicotine
Study: 7563559
Drug: 44‐mg/d dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44‐mg/d dose of nicotine patch therapy
Study: 7563559
Drug: Week 2
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Week 2 patch dose
Study: 27976801
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of all four antibacterial antibodies (anti-CBir1, anti-OmpC, anti-A4-Fla2, anti-Fla-X) at baseline
Study: 27976801
Drug: Baseline quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline quartile sum score for all six antimicrobial antibodies
Study: 25306557
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg benralizumab
Study: 25306557
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg benralizumab
Study: 25306557
Drug: benralizumab (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: benralizumab (any dose)
Study: 22039087
Drug: Preoperative CRT
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative CRT with 5‐fluorouracil (5‐FU) continuous infusion followed by surgery
Study: 19220764
Drug: New gustatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: New gustatory stimulant of salivary secretion containing weaker malic acid, fluoride, and xylitol
Study: 19220764
Drug: Traditional citric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional citric acid-based gustatory stimulant
Study: 17241860
Drug: MMX mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalamine 2.4 g/day
Study: 17241860
Drug: MMX mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMX mesalamine 4.8 g/day
Study: 17241860
Drug: ASACOL 2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASACOL 2.4 g/day
Study: 15066738
Drug: Tea tree
Normalized name: tea tree
DrugBank: Melaleuca alternifolia leaf (DB14372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea tree oil regimen (10% cream, 5% body wash for 5 days)
Study: 15066738
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (mupirocin 2% nasal ointment, chlorhexidine gluconate 4% soap, silver sulfadiazine 1% cream for 5 days)
Study: 15066738
Drug: Mupirocin 2%
Normalized name: MUPIROCIN 2% OINT
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin 2% nasal ointment
Study: 15066738
Drug: Tea tree
Normalized name: tea tree
DrugBank: Melaleuca alternifolia leaf (DB14372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea tree cream
Study: 15066738
Drug: Tea tree
Normalized name: tea tree
DrugBank: Melaleuca alternifolia leaf (DB14372)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea tree treatment
Study: 1888324
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment (special kind of behaviour therapy)
Study: 6337951
Drug: Captopril (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (450 mg/day)
Study: 6337951
Drug: Hydrochlorothiazide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (up to 100 mg/day)
Study: 1794215
Drug: Captopril monotherapy
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril monotherapy
Study: 22129616
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 0 ml (V0)
Study: 22129616
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 100 ml (V100)
Study: 22129616
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 300 ml (V300)
Study: 22129616
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (3 kcal/min) with gastric distension at 500 ml (V500)
Study: 22129616
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion (3 kcal/min) with gastric distension (all volumes)
Study: 16805931
Drug: Intraoperative fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative fentanyl with ketoprofen (1.5 mg kg‐1)
Study: 12505963
Drug: Interscalene group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene group (n = 20) received clonidine 150 micro g in 15 mL of saline through the catheter
Study: 12505963
Drug: Systemic group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic group (n = 20) received 15 mL of saline through the catheter and clonidine 150 micro g (1 mL) subcutaneously
Study: 9075128
Drug: felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 5 mg once daily for 4 weeks
Study: 8371932
Drug: Subcutaneous interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon alpha‐2a (3 million units/m2) every other day for 8 weeks
Study: 18984557
Drug: Sequential exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential exposure to program sections over 5 weeks
Study: 12410648
Drug: DDAVP (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (300 micro g) nasal spray
Study: 31764363
Drug: Perioperative intravenous
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative intravenous dexamethasone
Study: 26795265
Drug: Combined dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dietary supplement (2 capsules/day)
Study: 26795265
Drug: Combined dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined dietary supplement (10 or 50 mg/kg orally)
Study: 26251958
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 μg
Study: 26251958
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 μg
Study: 24070494
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate (SLM) 50 μg
Study: 24070494
Drug: Combination FP
Normalized name: FP-1096
DrugBank: FP-1096 (DB05310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination FP 100 μg + SLM 50 μg
Study: 24070494
Drug: Salmeterol (SLM)
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol (SLM) 10(‐8) mol/L with Fluticasone (FP) 10(‐9) mol/L
Study: 24070494
Drug: Salmeterol (SLM)
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol (SLM) 10(‐9) mol/L with Fluticasone (FP) 10(‐11) mol/L
Study: 20003200
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (Group 1; blood glucose concentration 4.4‐6.1 mmol/l)
Study: 20003200
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin treatment (Group 2; blood glucose level 7.0 mmol/l‐11.0 mmol/l)
Study: 11564247
Drug: High-dose mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose mannitol (HDM)
Study: 11564247
Drug: Conventional-dose mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional-dose mannitol
Study: 2510282
Drug: Rioprostil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rioprostil (600 micrograms, single oral dose)
Study: 31944277
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate gel 0.05%
Study: 28449910
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (bi-weekly educational classes)
Study: 23525434
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust inhalation
Study: 9874861
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 150 micrograms